quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·60d
PRRelease
Ocular Therapeutix Inc. logo

Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations

OCUL· Ocular Therapeutix Inc.
Health Care
Original source

Companies

  • OCUL
    Ocular Therapeutix Inc.
    Health Care

Recent analyst ratings

  • Sep 15UpdateChardan Capital Markets$21.00
  • Apr 8UpdateWilliam Blair-
  • Mar 18UpdateRBC Capital Mkts$17.00
  • Mar 11UpdateNeedham$15.00
  • Oct 16UpdateScotiabank-
  • Jun 20UpdateTD Cowen$11.00

Related

  • PR2d
    Ocular Therapeutix™ to Host Investor Day on June 17, 2026
  • PR10d
    Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • INSIDER10d
    SEC Form 4 filed by Dugel Pravin
  • PR11d
    Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD
  • PR23d
    Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Ocular Therapeutix Inc.
  • PR45d
    Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • SEC55d
    Ocular Therapeutix Inc. filed SEC Form 8-K: Regulation FD Disclosure
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022